Taltz-Zepbound Benefits Persist in Psoriatic Disease

Company: Eli Lilly · Drugs: Taltz (Ixekizumab) + Zepbound (Tirzepatide) · Trials: TOGETHER-PsO, TOGETHER-PsA (Phase 3b) · Indication: Psoriatic Disease with Obesity/Overweight · Date: August 31, 2026 Summary Lilly reported 52-week follow-up from two randomized, open-label Phase 3b trials pairing the IL-17A antibody Taltz with…